Simulations of the effects of DNA polymorphisms, transcriptional noise, and epigenetic differences within and among populations suggest highly divergent responses to drug dosage, resulting in considerable risk of adverse effects. These findings highlight the need for personalized calibration of drug dosage.
Introduction
Drug dosage selection must minimize adverse effects while maximizing efficacy. Here, using simulations of the effects of an antagonist drug on downstream gene expression levels, we show that inherent differences among individuals, and within the cells of individuals, lead to large differences in dosage requirements.
The effects of genetic polymorphisms on drug uptake and clearance rates are well known, and in cases such as warfarin [1] , dramatic. The simulations presented here focus on drug-action at the cellular level and assume optimal drug targeting, delivery and clearance rates. Surprisingly, we find that even below-average inter-individual variations in gene expression levels lead to considerable variations in response to drugs. Our results suggest a need for personalized drug dosage selection.
Gene expression variation is known to arise from at least three different mechanisms.
First, non-genetic factors such as age, gender, and health history are well known to affect gene expression. Metabolic status [2] , smoking [3] , exercise [4] , and emotional state [5] have also been shown to modulate the expression of large numbers of genes by 2-fold or more. Second, inherent transcriptional noise in individual cells arises from random variations in cellular content, and the fact that transcription is a sequential process involving a small number of copies of each gene [6] . Measurements in single mammalian cells suggest a protein abundance coefficient-of-variation of 15-30%, and long-lasting (>24 hours) concentration changes [7] . Third, widespread DNA-sequence variations cause several-fold differences in gene expression both within and across populations [8] [9] [10] . These variations are observed in multiple cell types and affect a large proportion of genes in both healthy and diseased individuals. Genes involved in the immune system -a target of many drugs -appear to be particularly variable, both within and among populations [11] .
Here, using a simple kinetic model we show that -even under very conservative assumptions -unavoidable variations in gene expression result in highly divergent responses to the same drug dose, and lead to several-fold differences in optimum dosage.
Even individuals who appear to respond well to treatment are shown to harbor many nonresponsive cells. These effects highlight the need for personalized calibration of drug dosage. To translate the above dose-response distributions into illustrative measures of drug efficacy, Gene1 is defined to be adequately suppressed when its expression is less than 10% of its average expression in the diseased state. Similarly, Gene2 is defined to be adequately expressed when its expression exceeds half of its mean in healthy cells. At each drug dosage, we can now count the number of individuals in whom genes 1 and 2 have responded adequately to treatment. Fig. (1C) shows the resulting dose-response curve. Note that Gene2 -whose expression is noisier than Gene1 -has a more graded response and requires a higher drug dose. Fig. (1C) can be used to define a therapeutic window for our hypothetical drug. At lower drug doses too few people benefit from treatment (<95% of cells responding). At very high doses (gray box), the drug may have adverse effects. The area between these regions defines the therapeutic window for the drug.
Results

Fig
Next, inherent gene expression noise within cells was mimicked by randomly varying all kinetic parameters of the network in Fig. (1A) by an amount not exceeding 10%. This noise level results in an mRNA1 variance to mean ratio well below that measured [13] Fig. (2B) , all but one of the 1000 individuals in Fig. (1) responded to treatment. Using the same treatment success criteria as Fig. (1) , over 12% (128/1000) of population (i) fail to respond, while population (ii) receives a 2.5 -4 fold overdose (with potential adverse effects). In fact, no single dosage is satisfactory for both populations, as illustrated by the dose-response curves of Fig. (2C) .
Finally, Fig. (2D) shows that over 17% (177/1000) of the cells of the average individual in population (i) do not respond to treatment, though the individual is deemed to have responded. In other words, at the dosage optimum for the population in Fig. (1) , less than half of population (i) is treated successfully.
Discussion
The simulation studies presented here suggest dramatic differences in drug dosage requirements among individuals, even within genetic populations. The model presented here is intended for illustrative purposes. The two downstream genes modeled represent two common archetypes: genes directly downstream of a signaling pathway, and genes regulated by signaling-activated transcription factors.
In this study, the complexity of the model and number of free parameters were kept to a minimum in order to highlight the fundamental nature of the observations reported.
Because there are no feedbacks and no cross-talk paths to other pathways, our model is monotonic in its behavior, and not sensitive to its parameter values. Any set of parameter values that allow the two genes in the model to switch on and off according to the availability of ligand and/or drug molecules, result in model behaviors similar to those reported here.
Real biological pathways have many cross-connections and feedbacks. Such linkages can create both sensitivity and robustness. In particular, we and others have shown that some genetic regulatory networks are capable of filtering out gene expression variability (see for example [14, 15] ). To date, mechanisms that provide robustness to gene expression variations have only been discovered in a limited number of cases. Whether such "noisefiltering" occurs downstream of common drug targets is not known. We hope that our findings will motivate urgent experimental evaluation of the extent of gene expression variability downstream of known drug targets. A related challenge will be the development of quantitative biomarkers that will allow cheap, fast, and accurate measurement of patient response to drugs.
Conclusions
Personal genomics is widely expected to revolutionize drug development by enabling the design of customized drugs for population-specific susceptibilities. The simulation studies presented in this paper suggest that even for population-specific drugs, and even after correcting for differences in drug uptake and clearance rates, dosage levels may need to be optimized on a person-by-person basis.
The recent sequencing of the diploid genome of a single individual [16] has revealed a surprisingly large number of genomic polymorphisms, with multiple variants affecting individual pathways [17] . Nonlinear interactions among variants can lead to still greater gene expression variations than modeled here. Thus, the need for personalized drug dosage selection may be even more pressing than indicated by the conservative estimates presented here.
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